AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00366834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron oral tablets
Study NCT00410202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Tablets, Oral, 100mg, once daily, 100 weeks
Study NCT00366834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: casopitant placebo
Study NCT00642473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Participants will receive erlotinib 150 milligrams (mg) orally daily for 4 weeks.
Study NCT00642473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Actavis
Description: Metronidazole actavis 1% topical cream will be applied on the face and chest twice daily for 4 weeks.
Study NCT00642473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-active Moisturizing Cream
Description: Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
Study NCT03219918 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoRings II Distal Attachment
Description: Colonoscopy cap
Study NCT04407481 — intervention group
Intervention type: DRUG
Intervention: Aminohippurate Sodium Inj 20%
Description: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Study NCT04407481 — intervention group
Intervention type: DRUG
Intervention: Iohexol Inj 300 milligrams per milliliter (MG/ML)
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Study NCT04407481 — intervention group
Intervention type: RADIATION
Intervention: PET/CT Scan
Description: Imaging used to visualize the kidneys and quantify renal metabolic activity
Study NCT01296438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin)
Study NCT01296438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin)
Study NCT01178073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ambrisentan
Description: ambrisentan (target dose: 10mg)
Study NCT01178073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: tadalafil (target dose: 40mg)
Study NCT02471976 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: strategy promoting early consideration and collegiate vulnerability of patients
Description: One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
Study NCT00484718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Description: oral, 100 mg bid
Study NCT00484718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: oral, 20 mg bid
Study NCT02193347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEPIDH1M vaccine
Description: PEPIDH1M vaccine is made up of 500 µg of 25 amino acid peptide administered with 150 µg of GM-CSF mixed 1:1 with Montanide ISA 51 administered intradermally. The peptide vaccine is administered in the groin area approximately 10 cm below the inguinal ligament.
Study NCT02193347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus-Diphtheria Toxoid (Td)
Description: After consent has been signed, all subjects will undergo standard of care vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly (I.M.) into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Within 48 hours of leukapheresis, subjects will receive a vaccine site pre-conditioning as a single dose of Td toxoid (1 flocculation unit, Lf, in a total volume of 0.4 mLs saline) administered intradermally to the right side of the groin one day prior to receiving the first PEPIDH1M vaccine.
Study NCT00484718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral bid
Study NCT02636374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: A fifteen minute recording of gentle music together with soft talking to guide relaxation.
Study NCT04756869 — intervention group
Intervention type: OTHER
Intervention: COVID-19 Monitoring Using Wearable Sensors and Smartphone Technology
Description: Health care workers are on-study for 30 days, in which they wear a smart watch and temperature patches up to daily. Subjects also may provide nasal and saliva samples up to daily during the study period, and they may opt-in to blood samples lasting up to 1 year after study completion. Through a smartphone app, participants complete surveys at baseline and at study completion, as well as daily mood surveys and symptom-reporting surveys. Finally, exit interviews occur at the end of the study period, and follow-up interviews may occur at specified timepoints up to 1 year after study completion.
Study NCT01461278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent supra
Description: Cataract surgery and implantation of one iStent supra
Study NCT01461278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Cataract surgery alone
Study NCT01461278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract surgery alone
Study NCT03356054 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: R-DHAP
Description: 3 cycles q 3 weeks
Study NCT03356054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: 3 cycles q 3 weeks added to R-DHAP
Study NCT00861536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG Fresenius
Description: Day 0: 9 mg/kg bw bolus Days 1-4: 3 mg/kg bw/d
Study NCT00861536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobuline Genzyme
Description: Day 0-3: 1.5 mg/kg bw/d
Study NCT01917929 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Secur-Fit Advanced Hip Stem
Description: Straight femoral stem intended for cementless, press-fit application.
Study NCT01302379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Study NCT01302379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Study NCT01302379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Study NCT01302379 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.
Study NCT01302379 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard printed dietary guidelines
Description: Set of standard health education materials provided to participants at single time point (immediately after randomization)
Study NCT01302379 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard printed dietary guidelines
Description: Set of standard health education materials provided to participants at single time point (immediately after randomization)
Study NCT03589781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mikei Red Reishi Essence EX
Description: Dosage is 490 mg per capsule, 3 capsules twice a day with food or water. Total of 6 capsules per day.
Study NCT03589781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo. Consume 3 capsules twice a day with food or water. Total of 6 capsules per day.
Study NCT02826850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saphenous Nerve
Description: Saphenous nerve neurotomy by radiofrequency, guided by ultrasound.
Study NCT03862521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: Low carbohydrate diet
Study NCT02826850 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Genicular nerves
Description: Genicular nerves neurotomy by radiofrequency, guided by fluoroscopy
Study NCT03986151 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiography +/- percutaneous coronary intervention
Description: Comparison of the conventional radial approach with the distal radial approach (anatomical snuffbox)
Study NCT03986151 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiography +/- percutaneous coronary intervention
Description: Comparison of the conventional radial approach with the distal radial approach (anatomical snuffbox)
Study NCT03862521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate diet
Description: Very low carbohydrate diet
Study NCT04530344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: ruxolitinib cream is a topical formulation applied as a thin film to affected areas BID.
Study NCT04530344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study NCT00832780 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation
Description: A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the planning target volume. Dose homogeneity +/- 5%.
Study NCT02193347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Subjects are treated with temozolomide (TMZ) at a targeted dose of 50-100mg/m2/d for 21 days every 28 days for up to 12 cycles. Subjects that have transitioned to a higher grade brain tumor at time of surgery will receive TMZ and radiation therapy per standard of care before starting TMZ cycles.
Study NCT03199534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A 50u
Description: Subject will receive injection of 50u Botulinum toxin A with local sedation as an office procedure.
Study NCT03199534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A 100u
Description: Subject will receive injection of 100u Botulinum toxin A in either the office or while anesthetized.
Study NCT03199534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A 150u
Description: Subject will receive injection of 150u Botulinum toxin A while anesthetized.
Study NCT04069169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intervention group (A) will receive P-IVLT in addition to the standard multimodal analgesia. P-IVLT will consist of 1 mg/kg bolus at start of anesthesia (T0), followed by 2 mg·kg-1·hr-1 infusion for 8 hours (T1), then continued at 1 mg·kg-1·hr-1 infusion thereafter and postoperatively until T0 + 48 hours (T2).
Study NCT04069169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Control group (B) will receive a placebo (0.9% sodium chloride also known as normal saline), made to mimic the intervention protocol described above, in addition to the standard multimodal analgesia.
Study NCT00952562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: Capsule cholecalciferol 1000 IU, 3 capsules per day for 16 weeks
Study NCT00952562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Empty capsules, 3 capsules per day for 16 weeks
Study NCT01258699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiocacid HR Tab 600mg
Description: 600mg for 1 day
Study NCT01258699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BK-C-0701 320mg
Description: 320mg for 1 day
Study NCT01258699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BK-C-0701 480mg
Description: 480mg for 1 day
Study NCT04019704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05
Description: Oral AXS-05 tablets, taken daily for 6 weeks.
Study NCT04019704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match oral AXS-05 tablets, taken daily for 6 weeks.
Study NCT01348906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intermittent normoxia
Description: 3 cycles of 5/5 min normoxia/hyperoxic reperfusion during cardioplegia arrest in adult valve replacement
Study NCT02065011 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Blood draw for the laboratory assessment
Study NCT03109067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized meal
Description: Blood samples performed at 5 different times : H0 before the meal, H2, H4, H6 and H8 after the meal
Study NCT04427345 — intervention group
Intervention type: OTHER
Intervention: Predictive factors for clinical response in patients with COVID-19.
Description: Identify the risk factors for intra-hospital mortality in patients hospitalized in the COVID + hospital wards of the San Gerardo hospital and build a prognostic score through which it is possible to define a stratification that immediately guides the therapeutic choices and the intensity of care .
Study NCT03003065 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temoporfin
Description: A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours
Study NCT02475863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warfarin Dosing Aid
Description: A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin
Study NCT02475863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice
Description: Warfarin dose adjustments according to standard unit protocol
Study NCT02244957 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bi-level positive airway pressure (BPAP)
Description: Overlap patients randomized to BPAP will be titrated as per American Academy of Sleep Medicine (AASM) guidelines and oxygen if needed based on saturations \<88% while on stable bi-level settings.
Study NCT02244957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nocturnal oxygen
Description: Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
Study NCT04304196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEMPO
Description: TEMPO is designed as a 7- to 10-week, web-based intervention containing 5 modules to pace patient-caregiver dyads' learning, avoid information overload, and allow sufficient practice time in-between modules . Each module is organized along six key components: needs assessment, tailored information and skills training, goal setting and action planning, motivational and social support, monitoring, automated feedback, and addressing time demands. Overall, modules aim to a) increase dyads' confidence in using strategies to address key psychosocial issues in the acute survivorship phase (e.g., dealing with stress and worry, communicating with partner and family, uncertainty management) and b) assist dyads in developing the self-regulatory skills necessary to meet the physical activity guidelines. Each module specifies a series of online (i.e. didactic material and interactive worksheets) and offline activities (i.e. practicing the proposed skills).
Study NCT04304196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team, but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices). Participants will be given access to the TEMPO website after having completed their final questionnaire, as thanks for participating.
Study NCT04349098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Participants will receive 20 mg of selinexor.
Study NCT04349098 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 20 mg of placebo matched to selinexor.
Study NCT04126785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise in Heated Water-Based
Description: High intensity interval exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level of rate perceived exertion (RPE) scale, followed by 21 min of HIIE, alternating 1 min of jogging/running at 15-17 (hard-very hard) level with 2 min of walking at 9-11 (very light-fairly light) level of RPE.
Study NCT04126785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Moderate Exercise in Heated Water-Based
Description: Continuous moderate exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level (light) of RPE, followed by 26 min of MICE, walking at 11-13 (fairly light)level of RPE.
Study NCT04126785 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: CON session will perform at controlled heated water-base (30 e 32 ºC). Subject will be seated in a chair and submerged at the until xiphoid process level for 30 min.
Study NCT00983801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Vial, Injection, Intravenous (IV), 40 mg/m\^2, Every 21 days, Up to 8 cycles or until disease progression or intolerable toxicity. Additional treatment was given in agreement by both the investigator and sponsor. Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day (3 week) cycle provided the participant met the retreatment criteria.
Study NCT03921905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ABI measurement
Description: ABI measurement wil be done with an automatic device to diagnose PAD in patients with CAD
Study NCT04573478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrasentan
Description: Film-coated tablet
Study NCT04573478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study NCT01127958 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI with a drug-eluting balloon
Description: PCI with a drug-eluting balloon for in-stent restenosis
Study NCT01127958 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI with a drug-eluting stent
Description: PCI with a drug-eluting stent for in-stent restenosis
Study NCT00779090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment manoeuvre
Description: Increase airway pressure during pressure controlled ventilation up to peak-airway pressure of 40 cmH20 and PEEP of 15 cmH20.
Study NCT03707340 — intervention group
Intervention type: DRUG
Intervention: Flibanserin Pill
Description: Eligible participants will begin treatment with flibanserin 100 mg orally daily at bedtime for 24-36 weeks and followed for a total of 52 weeks.
Study NCT03492385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB2452 Infusion
Description: 30 minute - 12 hour infusion
Study NCT05413031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: relative motion splint
Description: splint with ability to move the fingers
Study NCT05413031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: static splint
Description: splint with immobility of wrist, and fingers
Study NCT04171284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT-I10
Description: 200 mg, Q3W, maximum treatment up to six cycles
Study NCT04171284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 70-75mg per square meters of body surface area, Q3W, maximum treatment up to six cycles
Study NCT04171284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 70-75mg per square meters of body surface area, Q3W, maximum treatment up to six cycles
Study NCT04171284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg, Q3W, maximum treatment up to six cycles
Study NCT04171284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 200 mg, Q3W, maximum treatment up to six cycles
Study NCT02526173 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: RALP using full nerve sparing technique
Description: RALP using full nerve sparing technique
Study NCT02526173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RALP using full nerve sparing technique
Description: RALP using full nerve sparing technique